The MSK Therapeutics Accelerator is a strong fit for the venture as it provides tailored mentorship and access to drug development expertise, which aligns with the venture's goal of predicting drug resistance mutations. The accelerator's focus on innovative therapeutics for cancer also matches the venture's sector. However, the geography is US, which is not the primary target for the venture, but still a relevant market.